São Paulo, São Paulo, Brazil

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER V Study

The study will be designed to be a phased study with an initial enrolment of 25 subjects in phase 1. An interim analysis may be performed after phase 1 and the remainder (up to 65 subjects) may be enrolled as part of phase 2. The study shall not be blinded prior to, during or post the procedure. All patients undergoing an endovascular procedure requiring an arteriotomy created by 14 to 22 F sheaths, via the common femoral artery will be screened against the inclusion/exclusion criteria. If the patient meets the requirements of the clinical investigation, they shall be invited to participate, provide informed consent and shall subsequently be assigned a 'Subject Number'. The closure will be percutaneous. An optional adjunctive endovascular balloon may be used to control bleeding. All safety data from the study will be assessed by the Data Safety Monitoring Committee on a continuous basis. The Purpose of the Study is to assess safety and performance of the PerQseal® + Closure Device when used with the L PerQseal® Introducer to percutaneously close femoral artery punctures and to induce arterial haemostasis in patients undergoing endovascular procedures requiring an arteriotomy created by 14 to 22 F sheaths.

Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer

Please refer to uploaded Study Protocol

Goal-directed MIS Simulation Training With the LTB-Curriculum Prior to First Operations on Patients: Study Protocol for a Multi-centre Randomized Controlled Validation Trial (NOVICE)

Manuka Honey in Second- and Grafted Third-degree Burns

In plastic and reconstructive surgery, treatment strategies of second-degree burn wounds and split-skin grafted third-degree burn wounds aim at reducing infection and improving reepithelialization. Although previous studies indicate that burn patients benefit from wound dressings containing manuka honey, only a few studies can be found. Therefore, the aim of this study is to evaluate time to reepithelialization, pain, microbiology and handling of manuka honey dressings with second-degree burn wounds and split-skin grafted burn wounds.

The German ADPKD Tolvaptan Treatment Registry

A substantial number of ADPKD patients treated in our center or referred to our center for counseling are considered eligible for tolvaptan treatment and, thus, will be invited to enter the registry. Furthermore, many patients with ADPKD are treated by nephrologists in practices. We operate a network with many of these practices and will expand this network. Patients can be enrolled - after having obtained approval by the local ethics committee - at external sites (expected number: about 500 patients per year). We are also closely liaised with the German self-help group PKDCure (PKD Familiaere Zystennieren e.V.), which is dedicated to ADPKD-linked research. Recruitment of patients will be facilitated by intensified interacting with these groups. Usually, patients that are referred to our institution for evaluation or counseling are regularly seen once a year. No additional trial-related visits in our institution will be required which is in line with the observational nature of the trial. However, data recording is not restricted to parameters assessed at our center but does include also parameters assessed by the treating physician. SOPs (Standard Operating Procedures) that include further diagnostic tests like MRI are applied routinely in ADPKD patient management in our institution. The data obtained from these tests will be entered in the registry. At enrolment, clinical, laboratory data and imaging study findings are collected after obtaining informed consent. The parameters listed below constitute the core data set, additional parameters can be included if considered essential. Clinical data: - demographic data (sex, age, height, weight) - family history - genotype (if available) - extrarenal ADPKD manifestations - co-morbidities - medication - physical examination - blood pressure - no. of extrarenal and renal complications in the past 12 months (urinary tract infections, pain episodes, macrohematuria, kidney stones, hospital admissions, ...) Laboratory parameters include primarily (but not exclusively): - serum sodium - serum potassium - serum osmolality - serum creatinine - estimated glomerular filtration rate (eGFR) - serum urea - serum uric acid - whole blood count - liver enzymes, bilirubin - urinary sodium (spot and 24h-urine) - urinary potassium - urinary osmolality - urinary creatinine - urinary urea - urinary uric acid - urinary protein Imaging study parameters: - MRI - TKV (Total Kidney Volume) - ultrasound - (CT-scan if available) Registered patients will be provided with diaries for documentation of tolvaptan dose, adverse side effects etc. These diaries are collected on a yearly basis and the data are included in the registry. Additionally the patients will be asked to fill in a questionnaire regarding the current medication, complications of ADPKD etc. once a year as well as a commercially available SF-12 (quality of life assessment) form. Data capture will be done at yearly intervals starting at 12 months after enrolment. It includes the biochemical parameters and imaging study findings that have been obtained over the precedent 12 months. The following additional data will be obtained: - prescribed tolvaptan dose within the precedent 12 months - maximum dose of tolvaptan given in the precedent 12 months - weight, blood pressure - urine output - adverse effects - hospital admissions - occurrence of kidney pain, haematuria, or urinary tract infection - complications associated with extrarenal manifestations of ADPKD - data from diaries and questionnaires as mentioned above According to the observational character of this study, no additional blood samples, examinations or imaging studies are required per protocol.

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

This study is a Phase 3b in Canada Minors will not be enrolled in Denmark

Dermatitis During Adjuvant Irradiation for BREAst Cancer:

The main goal of this trial is to evaluate whether standard skin care supported by a reminder app is superior to standard skin care alone with respect to prevention of grade ≥2 radiation dermatitis in patients receiving adjuvant radiotherapy for invasive breast cancer. Radiation dermatitis will be assessed by an observer (specially trained nurse, technician, or physician) different from the person who performs the routine visit of the patient ("blinded observer concept"), at the start of radiotherapy and weekly during the course of radiotherapy, and at the end of the radiotherapy course (=EOT) according to CTCAE v5.0. Secondary aims include pain (radiation fields), patient satisfaction with the reminder app (Arm A), impact of the reminder app on the use of health technology (Arm A), and benefit from support by staff members and/or the UKSH academy regarding the use of the reminder app (Arm A). This is a multinational, randomized, active-controlled, open-label, multicenter, parallel-group trial, which compares the following treatments of radiation related skin toxicity in patients with breast cancer: Standard skin care supported by a reminder app (Arm A) vs. standard skin care alone (Arm B). Stratification will be done using the following prognostic factors: 1. Treatment volume: Breast or chest wall alone vs. breast or chest wall plus lymph nodes 2. Radiation boost: Yes vs. no 3. At least one risk factor of dermatitis: Yes vs. no Risk factors include chronic inflammatory disease, significant cardiovascular disease, and smoking history of >10 pack years. After registration, patients will be randomized in a 1:1 ratio to Arm A or Arm B for treatment of radiation related skin toxicity. A stratified block-randomization with random block size will be performed via electronic CRF. The results of the randomization will be visible only after the input of the stratification factors and only for the corresponding patient. This document will be kept at the institution which performs the randomization until the end of the study. Afterwards, the original randomization list will be kept in the trial master file at the trial center of the coordinating investigator for a minimum of 10 years after the final report. The randomization will be performed via electronic CRF centrally by an external company using its standard software. The proceeding for randomization is based on standard operating procedures (SOPs) of this company. Once the randomization is allocated to the patient it cannot be changed. In all patients, radiotherapy will be administered using hypo-fractionation with 40 Gy in 15 fractions of 2.667 Gy given on 5 days per week (overall treatment time = 3 weeks; day of 15th fraction = EOT), preferably with intensity-modulated radiotherapy (IMRT) or volumetric-modulated arc therapy (VMAT). Patients aged ≤50 years receive a sequential radiation boost to the tumor bed of 10 Gy in 5 fractions of 2.0 Gy (on 5 days per week) following whole-breast irradiation, resulting in an overall treatment time of 4 weeks (day of 20th fraction = EOT). This accounts also for patients aged ≥51 years with risk factors for local recurrence. Patients may receive concurrent systemic agents as part of their standard anticancer treatment, regardless of the participation in this trial. These agents may include tamoxifen, aromatase inhibitors, or capecitabine [10]. The systemic agents will be indicated and prescribed by treating medical oncologists or gynecologists outside this trial. Regarding dose, type and duration of treatment, contraindications, side effects, pharmacological characteristics and pharmaceutical details of these agents, please see the corresponding product information. Standard Skin Care alone (Arm B): From the start of radiotherapy, standard skin care has to be performed by the patient. This may vary at the participating centers. At the site in Lübeck, it includes fatty cream with 2-10% urea (fatty cream alone, if patients do not tolerate urea) and, in case of pruritus, addition of mometasone furoate cream. In case of grade ≥2 moist desquamation or grade ≥3 radiation dermatitis, each day antiseptic agents will be administered for wound cleansing followed by administration of silicon or calcium alginate bandage. This treatment will be continued until moist desquamation radiation disappears and radiation dermatitis improves to grade 2. Fatty cream with 2-10% urea is applied to the irradiated skin four times daily. Mometasone furoate cream: In addition to the fatty cream with 2-10% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily. Patients of Arm B will be informed about the importance of skin care prior to the start of radiotherapy and reminded during their radiotherapy course, when regularly seen by a radiation oncologist (maximum once a week). Standard Skin Care plus Reminder App (Arm A): From the start of radiotherapy, standard skin care has to be performed by the patient as described for Arm B. In addition, patients of Arm A are supported by a Reminder App, which is developed by the professional company Nextlabel OHG from Lübeck. The purpose of the app is to remind the patients in an intuitive, unobtrusive and supportive way to perform skin care. By default, patients are reminded four times a day, but they will also be able to define a notification schedule that best suits their personal needs. Questionnaire regarding the Reminder App and its impact on the use of health technology: At the end of their radiotherapy course (= EOT), the patients of Arm A will be asked to complete a questionnaire regarding their satisfaction with the Reminder App. In case of a dissatisfaction rate >20%, the reminder app is considered to require modifications before it can be used in future studies. In case of a dissatisfaction rate >40%, it will be considered not useful. This questionnaire also includes questions regarding the impact of the app on the use of health technology. Elderly patients aged ≥65 years will be compared to younger patients aged <65 years to identify potential differences between both age groups and the need for support regarding the use of the reminder app. Sample size calculation The primary goal of this randomized trial is to evaluate whether standard skin care supported by a reminder app is superior to standard skin care alone with respect to preventing grade ≥2 radiation dermatitis during adjuvant hypo-fractionated radiotherapy for breast cancer. According to sample size calculations, 131 patients are required per study arm within the Full Analysis Set. Considering that 2% of patients will not qualify for Full Analysis Set, a total of 268 patients should be randomized. The following analysis sets will be defined for this trial: Safety Analysis Set: All randomized participants who started radiotherapy. Full Analysis Set: All randomized patients who have started either therapy with arm A or with arm B and provide any data on the primary endpoint. The Full Analysis Set will be analyzed according to the Intention-to-Treat principle, i.e. patients will be analyzed in their initial group of randomization. Per Protocol Set: All patients of the Full Analysis Set excluding patients if any of the following criteria are met: - Administration of less than 75% of the planned radiation dose if the reason for discontinuation was any other than death or unacceptable toxicity - More than 50% missing data on the primary study endpoint All patients in the Per Protocol Set will be analyzed within their group of actual treatment received. Statistical analyses: All data recorded in the electronic case report forms describing the study population and toxicity will be analyzed descriptively. Categorical data will be presented in contingency tables with frequencies, percentages and their 95% confidence intervals. Continuous data will be summarized with at least the following: frequency (n), median, quartiles, mean, standard deviation (standard error), minimum and maximum. Number of patients with protocol deviations during the study and listings describing the deviations will be provided. In general, chi-square tests will be used to compare percentages in a two-by-two contingency table, replaced by Fisher´s exact test if the expected frequency in at least one cell of the associated table is less than 5. Stratified two-by-two contingency tables will be analyzed using Cochran-Mantel-Haenszel tests. Logistic regression models serve as multivariable methods for binary endpoint data. Comparison of ordinal variables between treatment arms will be performed using the asymptotic Wilcoxon-Mann-Whitney test, replaced by its exact version in case of ordinal categories with small number of categories and/or sparse data within categories. Any shift in location of quantitative variables between study groups will be performed with the Wilcoxon-Mann-Whitney tests as well. Time-to-event data will be analyzed by Kaplan-Meier methods, when merely non-informative censoring occurs. For statistical comparison, the log rank-test will be provided supplemented by multivariate Cox proportional hazards models. The data analysis will be performed according to the statistical analysis plan (SAP), and which will be finalized prior to database lock and prior to any statistical analysis. To evaluate the rate of patients experiencing grade ≥2 radiation dermatitis during their course of radiotherapy, the worst documented grade during radiotherapy and at EOT is considered, even if patients have missing visits or discontinue radiotherapy prematurely. This reflects the "treatment policy estimand" approach. The rate of patients experiencing grade ≥2 radiation dermatitis will be statistically compared using the Cochran-Mantel-Haenszel Chi-square test on a two-sided significance level of 5%. This test is the natural non-parametric extension of the Chi-square test for testing the treatment effect, while adjusting for the effects of the stratification variables used for randomization. In case of uneven distribution to stratification groups, which may result in very small groups the strata might be pooled for analysis. The decision to pool strata for the analysis will be made before data base lock and before the final analysis of the data. For further assessment of the robustness of the results, a logistic regression model for grade ≥2 radiation dermatitis will be applied including the parameters used for stratification. A model including additional patient characteristics will be fitted for exploratory purposes. The confirmatory evaluation will be performed within the Full Analysis Set; the Per Protocol Set serves for further sensitivity analyses. The visual analogue scale pain prior to radiotherapy, during radiotherapy and at EOT will be subjected to descriptive analyses. pain potential differences in pain between treatment arms, the scores will be subjected to descriptive analysis. For graphical visualization Box-Whisker diagrams will be provided. Moreover, the change from baseline values will be considered and subjected to descriptive analyses. Friedman tests and Wilcoxon-Mann Whitney tests may be applied for comparison of study visits. At the EOT-visit, patient satisfaction with the reminder app in arm A will be evaluated and subjected to standard statistical methods. In case of a dissatisfaction rate >20%, the reminder app needs modifications. In case of a dissatisfaction rate >40%, it will be considered not useful. In addition, the questions on the impact of the app on the use of health technology will be evaluated descriptively. Elderly patients aged ≥65 years will be compared to younger patients aged <65 years to identify potential differences between both age groups and the need for support regarding the use of the reminder app. Standard statistical tests serve as a tool for exploratory comparison of age groups.

A Non-interventional, Prospective Study With Benralizumab

This is a prospective observational study to investigate the asthma control and health realted quality of life (HRQL) of benralizumab treated patients in routine clinical practice, their asthma medication intake, and their changes in asthma medication during the study, up to 52 weeks. The asthma control will be analyzed by using the Asthma Control Test (ACT) and the Asthma Impairment and Risk Questionnaire (AIRQ®) at different timepoints during the study period either collected by the investigator or self-reported by the patient. In addition, health realted quality of life will be assessed at baseline and routine follow-up visits using the mini Asthma Quality of Life Questionnaire (miniAQLQ) which is collected by the investigator. To investigate the medication intake and assess the changes in asthma medication, the patients will record their weekly medication intake in a paper-based or an electronic medication diary throughout the study.

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

The study consists of a Screening Phase during which eligibility is confirmed, a Treatment Phase in which participants will be randomized and receive double blinded study drug to treat 2 qualifying HAE attacks (i.e., 2 Treatment Periods within the Treatment Phase), and an End-of-Study Follow-up Phase after the second attack treated with study drug. In addition, for adolescent participants (age ≥12 to <18 years), PK samples are collected after administration of deucrictibant at Day 1 in a non-attack state.